iBio Earnings Reports

iBio's Q4 2025 performance showed progress, with revenue reaching $200,000 and net loss narrowing to $4.46 million. The company continued advancing its preclinical pipeline targeting obesity and cardiometabolic diseases.

iBio reported a net loss of $4.9 million for the fiscal third quarter ended March 31, 2025, compared to a net loss of $2.6 million in the same period last year. The company strengthened its financial position with a $6.2 million warrant inducement equity raise in April, and reported positive non-human primate data for IBIO-600 and in-licensed a first-in-class Activin E antibody.

iBio reported revenue of $0.2 million for services provided to a collaborative partner and a net loss of $4.4 million, or $0.48 per share, for the second quarter ended Dec. 31, 2024. The company also highlighted advancements in its preclinical pipeline and key board appointments.

iBio reported no revenue for the first quarter ended September 30, 2024. The net loss from continuing operations was approximately $4.0 million, or $0.46 per share. Cash, cash equivalents and restricted cash totaled approximately $11.3 million.

iBio reported a transformational fiscal year 2024, marked by strategic business developments including expanding the AI-powered technology stack, the sale of the PD-1 asset to Otsuka Pharmaceutical, and entering into a collaboration with AstralBio. The company strengthened its financial position through capital raises and debt extinguishment. However, the audit report contained an explanatory paragraph related to the company's ability to continue as a going concern.

iBio reported no revenue for Q3 2024. The company's net loss from continuing operations was $2.6 million, or $0.71 per share. iBio focused on strategic partnerships, including a collaboration with AstralBio, and cash preservation, which led to a decrease in R&D and G&A expenses.

iBio reported its fiscal year 2023 results, revealing no revenue and a consolidated net loss of $65.0 million. The company's operating expenses decreased by 7% compared to the previous year. iBio held $4.3 million in cash and cash equivalents as of June 30, 2023.

iBio reported FY 2022 revenues of $2.4 million, a 1% increase over fiscal 2021. The company's net loss for the year was $50.3 million. iBio held $39.5 million in cash, cash equivalents, and investments as of June 30, 2022.

iBio reported a revenue increase of 154% compared to the previous year, driven by royalty revenue from licensing its plant-based drug manufacturing IP. The company's net loss increased due to growing investments in its pipeline and platform technologies. iBio is advancing its COVID-19 vaccine candidate and immuno-oncology asset, with plans to enter clinical trials in 2023.

iBio reported a decrease in revenue and an increase in net loss for the second quarter ended December 31, 2021. The company is focusing on advancing its pipeline and platform technologies while managing cash effectively.

iBio reported revenues of $211,000 for the first fiscal quarter ended September 30, 2021, a 49% decrease compared to the same period in 2020. The consolidated net loss for the quarter was $8.9 million, or $0.04 per share. The company had $82.3 million in cash and cash equivalents as of September 30, 2021.

iBio reported a revenue of $0.5 million for the fourth quarter ended June 30, 2021, a decrease of $0.6 million from Q4 FY2020, and a consolidated net gain of $0.1 million due to Settlement Income.

iBio reported its Q3 2021 financial results, with revenue increasing to $0.8 million compared to $0.1 million in the same period last year. The company's net loss was $7.7 million, or $0.04 per share, compared to a net loss of $4.7 million, or $0.06 per share, in the same period of 2020.

iBio reported an increase in revenue to $0.7 million, up from $0.3 million in the same quarter of the previous year. The company's operating expenses increased to $8.3 million, and the net loss attributable to iBio stockholders was $8.2 million, or $0.04 per share. As of December 31, 2020, iBio had cash and cash equivalents plus investments in debt securities of approximately $107.6 million.